NVCR - NovoCure Limited
NEXT EARNINGS:
Feb 26, 2026
(in 1 day)
EPS Est: $-0.41
|
Rev Est: $173.4M
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$33.50
DETAILS
HIGH:
$47.00
LOW:
$20.00
MEDIAN:
$33.50
CONSENSUS:
$33.50
UPSIDE:
185.35%
Market Cap:
1.31B
Volume:
2,230,516
Avg Volume:
1,834,713
52 Week Range:
9.82-22.3
Sector:
Healthcare
Industry:
Medical - Instruments & Supplies
Beta:
0.73
Last Dividend:
$N/A
Exchange:
NASDAQ
Country:
JE
Employees:
1,488
IPO Date:
2015-10-01
EPS (TTM):
-1.56
P/E Ratio:
-19.06
Revenue (TTM):
605.22M
Total Assets:
1.24B
Total Debt:
683.35M
Cash & Equiv:
163.77M
Rev Growth (5Y):
11.5%
EPS Growth (5Y):
N/A
FCF Growth (5Y):
N/A
ROCE:
-24.9%
Debt/Equity:
1.90
Earnings History
| Date | EPS Actual | EPS Est | EPS Surprise | Rev Actual | Rev Est | Rev Surprise |
|---|---|---|---|---|---|---|
| 2025-10-30 | $-0.33 | $-0.42 | +21.4% | $167.2M | $174.4M | -4.1% |
| 2025-07-24 | $-0.36 | $-0.39 | +7.7% | $158.8M | $158.8M | 0.0% |
| 2025-04-24 | $-0.31 | $-0.47 | +34.0% | $155.0M | $153.9M | +0.7% |
| 2025-02-27 | $-0.61 | $-0.34 | -79.4% | $161.3M | $147.6M | +9.3% |
| 2024-10-30 | $-0.28 | $-0.34 | +17.6% | $155.1M | $153.0M | +1.3% |
| 2024-07-25 | $-0.31 | $-0.40 | +22.5% | $150.4M | $143.8M | +4.5% |
| 2024-05-02 | $-0.36 | $-0.43 | +16.3% | $138.5M | $135.8M | +2.0% |
| 2024-02-22 | $-0.45 | $-0.53 | +15.1% | $133.8M | $131.8M | +1.5% |
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 605.22M | 509.34M | 537.84M | 535.03M | 494.37M | 351.32M | 248.07M | 177.03M | 82.89M | 33.09M | 15.49M | 10.36M |
| Net Income | (168.63M) | (207.04M) | (92.53M) | (58.35M) | 19.81M | (7.23M) | (63.56M) | (61.66M) | (131.84M) | (111.58M) | (80.68M) | (77.37M) |
| EPS | -1.56 | -1.95 | -0.88 | -0.56 | 0.20 | -0.07 | -0.69 | -0.70 | -1.54 | -1.34 | -1.12 | -6.43 |
| Total Assets | 1.24B | 1.15B | 1.19B | 1.14B | 1.05B | 479.45M | 339.79M | 265.30M | 282.08M | 307.34M | 117.88M | 188.91M |
| Total Debt | 683.35M | 596.24M | 584.27M | 581.90M | 450.68M | 168.20M | 149.27M | 97.34M | 96.23M | 23.10M | 321,000 | 346,000 |
| Cash & Equivalents | 163.77M | 240.82M | 115.33M | 209.61M | 246.17M | 179.42M | 140.62M | 78.59M | 99.78M | 119.42M | 57.61M | 175.89M |
| Operating Cash Flow | (26.37M) | (73.34M) | 30.79M | 82.76M | 99.15M | 26.62M | (1.86M) | (33.13M) | (107.59M) | (99.88M) | (74.24M) | (52.72M) |
| Free Cash Flow | (69.22M) | (100.43M) | 9.43M | 58.59M | 84.18M | 16.14M | (8.58M) | (40.50M) | (125.26M) | (110.16M) | (76.56M) | (56.34M) |
| FCF per Share | -0.64 | -0.94 | 0.09 | 0.57 | 0.83 | 0.17 | -0.09 | -0.46 | -1.46 | -1.32 | -1.06 | -4.68 |
| Book Value | 360.18M | 362.50M | 441.17M | 410.49M | 476.53M | 217.79M | 112.26M | 113.56M | 142.34M | 250.82M | 97.88M | 171.78M |
| Cash & ST Investments | 959.87M | 910.62M | 969.42M | 938.51M | 854.08M | 328.19M | 245.88M | 183.31M | 219.63M | 269.42M | 102.61M | 175.89M |
| ROC Equity | -0.47 | -0.57 | -0.21 | -0.14 | 0.04 | -0.03 | -0.57 | -0.54 | -0.93 | -0.44 | -0.82 | -0.45 |